Theriva Biologics, Inc.

NYSEAM:TOVX Stock Report

Market Cap: US$3.4m

Theriva Biologics Past Earnings Performance

Past criteria checks 0/6

Theriva Biologics's earnings have been declining at an average annual rate of -4.4%, while the Biotechs industry saw earnings growing at 19.1% annually.

Key information

-4.4%

Earnings growth rate

56.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-108.3%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Mar 07
David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

Feb 04
Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

Revenue & Expenses Breakdown

How Theriva Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSEAM:TOVX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-27713
30 Jun 240-22715
31 Mar 240-19815
31 Dec 230-18814
30 Sep 230-19813
30 Jun 230-21912
31 Mar 230-20812
31 Dec 220-20812
30 Sep 220-19811
30 Jun 220-17711
31 Mar 220-1679
31 Dec 210-2368
30 Sep 210-2156
30 Jun 210-2055
31 Mar 210-2155
31 Dec 200-1355
30 Sep 200-1356
30 Jun 200-1559
31 Mar 200-16510
31 Dec 190-16511
30 Sep 190-28411
30 Jun 190-26510
31 Mar 190-27511
31 Dec 180-25612
30 Sep 180-8713
30 Jun 180-22715
31 Mar 180-22716
31 Dec 170-22819
30 Sep 170-27922
30 Jun 170-18925
31 Mar 170-191027
31 Dec 160-271029
30 Sep 160-36931
30 Jun 160-34934
31 Mar 160-42935
31 Dec 150-44833
30 Sep 150-39729
30 Jun 150-37723
31 Mar 150-28718
31 Dec 140-20614
30 Sep 140-18512
30 Jun 140-16610
31 Mar 140-1458

Quality Earnings: TOVX is currently unprofitable.

Growing Profit Margin: TOVX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TOVX is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.

Accelerating Growth: Unable to compare TOVX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TOVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: TOVX has a negative Return on Equity (-108.35%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies